Anlotinib (AL3818) plus pemetrexed in patients with recurrent platinum-resistant advanced epithelial ovarian cancer: A single-arm, open-label, phase II study.

被引：0
|
作者：
Zhang, Yanna
Chen, Jueming
Wei, Wei
Zheng, Lie
Li, Han
Feng, Yanling
Wan, Ting
Qiu, Jiaqi
Jiang, Xingyu
Xiong, Ying
Li, Jundong
Song, Libing
Liu, Jihong
Huang, He
机构：
[1] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Dept Gynecol Oncol, State Key Lab Oncol South China,Canc Ctr, Guangzhou, Peoples R China
[2] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Dept Imaging, State Key Lab Oncol South China,Canc Ctr, Guangzhou, Peoples R China
[3] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Dept Biotherapy, State Key Lab Oncol South China,Canc Ctr, Guangzhou, Peoples R China
[4] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Dept Expt Res, State Key Lab Oncol South China,Canc Ctr, Guangzhou, Peoples R China
[5] Sun Yat Sen Univ, Canc Ctr, Collaborat Innovat Ctr Canc Med, Dept Med Oncol,State Key Lab Oncol South China, Guangzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e18078
引用
收藏
页数：2
相关论文
共 50 条
  • [21] COMBINATION OF NIRAPARIB AND ANLOTINIB IN PATIENTS WITH RECURRENT OR METASTATIC ENDOMETRIAL CANCER: AN OPEN-LABEL, SINGLE-ARM, TWO-STAGE, PHASE II STUDY
    Ren, Yulan
    Lu, Jing
    Tian, Wenjuan
    Li, Haiming
    Wang, Huaying
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 : A107 - A107
  • [22] Famitinib malate plus camrelizumab for recurrent platinum-resistant ovarian/fallopian tube/primary peritoneal cancer and advanced cervical cancer: An open-label, multicenter phase II study
    Xia, L.
    Zhou, Q.
    Zhang, Y.
    Gao, Y.
    Hu, W.
    Pan, M.
    Lou, G.
    Wang, L.
    Shi, H.
    Zhu, J.
    Sun, H.
    Wang, X.
    Wang, Q.
    Wu, X.
    ANNALS OF ONCOLOGY, 2020, 31 : S630 - S630
  • [23] Preliminary results of anlotinib and niraparib dual therapy evaluation in platinum-resistant recurrent ovarian cancer (ANNIE): A multicenter, single-arm, phase II trial
    Liu, J.
    Liu, G.
    Li, J.
    Feng, Y.
    Huang, H.
    Wan, T.
    Huang, Q.
    Xian, B.
    Kong, B.
    Lin, A.
    ANNALS OF ONCOLOGY, 2021, 32 : S736 - S736
  • [24] Anlotinib plus sintilimab as first-line treatment for patients with advanced colorectal cancer (APICAL-CRC): An open-label, single-arm, phase II study
    Wang, Z.
    Qin, B.
    Ye, C.
    Wang, M.
    Yuan, L.
    Yao, H.
    Jiao, X.
    Liu, K.
    Sun, L.
    Dai, W.
    Ling, Y.
    Wu, Y.
    Chen, S.
    Zhang, Y.
    Shi, D.
    Duan, X.
    Zhong, X.
    He, X.
    Zhai, W.
    Zang, Y.
    ANNALS OF ONCOLOGY, 2024, 35 : S1433 - S1433
  • [25] Adavosertib with chemotherapy (CT) in patients (pts) with platinum-resistant ovarian cancer (PPROC): An open label, four-arm, phase II study.
    Moore, Kathleen N.
    Chambers, Setsuko K.
    Hamilton, Erika Paige
    Chen, Lee-May
    Oza, Amit M.
    Ghamande, Sharad A.
    Konecny, Gottfried E.
    Plaxe, Steven C.
    Spitz, Daniel Lewis
    Geenen, Jill J. J.
    Troso-Sandoval, Tiffany A.
    Cragun, Janiel M.
    Imedio, Esteban Rodrigo
    Kumar, Sanjeev
    Mugundu, Ganesh M.
    Lai, Zhongwu
    Chmielecki, Juliann
    Jones, Suzanne Fields
    Spigel, David R.
    Cadoo, Karen Anne
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [26] Apatinib plus camrelizumab in patients with advanced cervical cancer: A multicentre, open-label, single-arm, phase II trial
    Huang, X.
    Shen, J.
    Xiong, Y.
    Wang, Y.
    Cao, X.
    He, M.
    Zou, G.
    Deng, Y.
    Wang, X.
    Lan, C.
    GYNECOLOGIC ONCOLOGY, 2020, 159 : 43 - 43
  • [27] Camrelizumab Plus Apatinib in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma: An Open-Label, Single-Arm, Phase II Study
    Ding, Xi
    Zhang, Wei-Jing
    You, Rui
    Zou, Xiong
    Wang, Zhi-Qiang
    Ouyang, Yan-Feng
    Peng, Lan
    Liu, You-Ping
    Duan, Chong-Yang
    Yang, Qi
    Lin, Chao
    Xie, Yu-Long
    Chen, Si-Yuan
    Liu, Yong-Long
    Gu, Chen-Mei
    Xie, Ruo-Qi
    Huang, Pei-Yu
    Hong, Ming-Huang
    Hua, Yi-Jun
    Chen, Ming-Yuan
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (14) : 2571 - +
  • [28] Anlotinib plus tislelizumab combined with chemotherapy as neoadjuvant treatment in triple-negative breast cancer: A prospective, single-arm, open-label phase II study.
    Luo, Jing
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [29] A prospective, single-arm, open-label, phase II clinical trial on efficacy and safety of cadonilimab plus anlotinib for recurrent, metastatic or persistent cervical cancer
    Yang, Chunxu
    Sun, Shaoxing
    Xiang, Qingming
    Chen, Min
    Mei, Zijie
    Wu, Qiuji
    Qiu, Hui
    GYNECOLOGIC ONCOLOGY, 2024, 190 : S290 - S290
  • [30] Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: An Open-Label, Four-Arm, Phase II Study
    Moore, Kathleen N.
    Chambers, Setsuko K.
    Hamilton, Erika P.
    Chen, Lee-May
    Oza, Amit M.
    Ghamande, Sharad A.
    Konecny, Gottfried E.
    Plaxe, Steven C.
    Spitz, Daniel L.
    Geenen, Jill J. J.
    Troso-Sandoval, Tiffany A.
    Cragun, Janiel M.
    Imedio, Esteban Rodrigo
    Kumar, Sanjeev
    Mugundu, Ganesh M.
    Lai, Zhongwu
    Chmielecki, Juliann
    Jones, Suzanne F.
    Spigel, David R.
    Cadoo, Karen A.
    CLINICAL CANCER RESEARCH, 2022, 28 (01) : 36 - 44
12345